BR112021026556A2 - Composto tricíclico, método de preparação para ele e uso dele - Google Patents

Composto tricíclico, método de preparação para ele e uso dele

Info

Publication number
BR112021026556A2
BR112021026556A2 BR112021026556A BR112021026556A BR112021026556A2 BR 112021026556 A2 BR112021026556 A2 BR 112021026556A2 BR 112021026556 A BR112021026556 A BR 112021026556A BR 112021026556 A BR112021026556 A BR 112021026556A BR 112021026556 A2 BR112021026556 A2 BR 112021026556A2
Authority
BR
Brazil
Prior art keywords
preparation
tricyclic compound
compound
tricyclic
formula
Prior art date
Application number
BR112021026556A
Other languages
English (en)
Inventor
Haibing Guo
Jianbiao Peng
Jiangwei Wang
Qiong Zhang
Shan Yao
Shuchun Guo
Yan Ye
Yong Zhang
Zhangping Kang
Original Assignee
Jiangxi Jemincare Group Co Ltd
Shanghai Jemincare Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Jemincare Group Co Ltd, Shanghai Jemincare Pharmaceuticals Co Ltd filed Critical Jiangxi Jemincare Group Co Ltd
Publication of BR112021026556A2 publication Critical patent/BR112021026556A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto tricíclico, método de preparação para ele e uso dele. um composto representado pela fórmula (i), um isômero óptico dele e um sal farmaceuticamente aceitável dele, bem como uma aplicação do referido composto como um inibidor do fxia.
BR112021026556A 2019-06-28 2020-06-28 Composto tricíclico, método de preparação para ele e uso dele BR112021026556A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910578620 2019-06-28
CN202010129623 2020-02-28
CN202010561350 2020-06-18
PCT/CN2020/098412 WO2020259668A1 (zh) 2019-06-28 2020-06-28 三并环类化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112021026556A2 true BR112021026556A2 (pt) 2022-02-15

Family

ID=74060758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026556A BR112021026556A2 (pt) 2019-06-28 2020-06-28 Composto tricíclico, método de preparação para ele e uso dele

Country Status (11)

Country Link
US (1) US11518766B2 (pt)
EP (1) EP3998263A4 (pt)
JP (1) JP7222123B2 (pt)
KR (1) KR102500570B1 (pt)
CN (1) CN114026087B (pt)
AU (1) AU2020301451B2 (pt)
BR (1) BR112021026556A2 (pt)
CA (1) CA3145111C (pt)
IL (1) IL289416B2 (pt)
TW (1) TW202115057A (pt)
WO (1) WO2020259668A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022013417A1 (en) * 2020-07-17 2022-01-20 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023002984A1 (ja) * 2021-07-20 2023-01-26 小野薬品工業株式会社 イミダゾール化合物の製造方法
TWI833610B (zh) * 2022-03-21 2024-02-21 大陸商上海濟煜醫藥科技有限公司 三并環類化合物製備方法及其中間體

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
ES2765891T3 (es) 2011-12-21 2020-06-11 Ono Pharmaceutical Co Derivados de piridinona y pirimidinona como inhibidores del factor XIa
JP2015083542A (ja) * 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
BR112017012146B1 (pt) * 2014-12-10 2023-11-21 Ono Pharmaceutical Co., Ltd Composto derivado de di-hidroindolizinona, seu uso, composição farmacêutica e inibidor de fxia
US10081617B2 (en) * 2015-04-16 2018-09-25 Merck Sharp & Dohme Corp. Factor XIa inhibitors
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
US20220251095A1 (en) 2022-08-11
IL289416B (en) 2022-12-01
JP7222123B2 (ja) 2023-02-14
AU2020301451B2 (en) 2023-02-16
KR102500570B1 (ko) 2023-02-16
CA3145111C (en) 2023-01-24
EP3998263A4 (en) 2023-09-06
KR20220020395A (ko) 2022-02-18
TW202115057A (zh) 2021-04-16
CA3145111A1 (en) 2020-12-30
JP2022530718A (ja) 2022-06-30
AU2020301451A1 (en) 2022-02-24
IL289416B2 (en) 2023-04-01
US11518766B2 (en) 2022-12-06
CN114026087A (zh) 2022-02-08
EP3998263A1 (en) 2022-05-18
IL289416A (en) 2022-02-01
WO2020259668A1 (zh) 2020-12-30
CN114026087B (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
BR112021026556A2 (pt) Composto tricíclico, método de preparação para ele e uso dele
CO2022004686A2 (es) Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
ECSP22046699A (es) Inhibidores de kras g12c
UY38057A (es) Inhibidores de sarcómero cardíaco
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
CL2021000361A1 (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
UY37073A (es) Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
ECSP10010657A (es) Nuevos compuestos tricíclicos
CO2017012594A2 (es) Moduladores de receptor nuclear
EA202193015A1 (ru) Ингибиторы cdk
CL2021000196A1 (es) Método de tratamiento de la epilepsia
CO2022002336A2 (es) Compuestos heterocíclicos
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
UY37941A (es) Derivados de bencimidazol y sus usos
CY1125355T1 (el) Πεντακυκλικη ενωση
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
CU24661B1 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
CO2021017202A2 (es) Compuestos tricíclicos
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen